Skip to content

Clinical trials

Graft vs Host Disease trials in Brazil

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Graft vs Host Disease Country / region: Brazil Clear all

12 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20051
20081
20121
20151
20181
20202
20241
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed5
Not yet recruiting2
Recruiting2
Unknown status2
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hospital Israelita Albert Einstein2
Wyeth is now a wholly owned subsidiary of Pfizer2
GIANCARLO FATOBENE1
Grupo de Estudos Multicentricos em Onco-Hematologia1
Hospital de Clinicas de Porto Alegre1
Instituto Nacional de Cancer, Brazil1
Mallinckrodt1
Novartis Pharmaceuticals1
Pontifícia Universidade Católica do Paraná1
University of Sao Paulo General Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Graft vs Host Disease12
Hematologic Neoplasms2
Leukemia, Myeloid, Acute2
Myelodysplastic Syndromes2
Precursor Cell Lymphoblastic Leukemia-Lymphoma2
Renal Insufficiency2
Bronchiolitis Obliterans Syndrome1
Hodgkin Disease1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive1
Leukemia, Myelomonocytic, Chronic1

Trials

Showing 76 to 12 of 12. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.